Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
Date:2/5/2009

ical trial comparing Amigal to placebo based on a surrogate primary endpoint of the change in the amount of kidney GL-3, the substrate that accumulates in the cells of Fabry patients. Amicus is continuing discussions with the FDA through a Special Protocol Assessment (SPA) procedure that it commenced in the fourth quarter of 2008 to finalize how the primary endpoint will be measured. The Company is expecting to finalize the protocol in the second quarter of this year.

Based on discussions with the European Medicines Agency (EMEA) in the fourth quarter of 2008, the Company plans to initiate a separate clinical trial designed to evaluate the safety and efficacy of Amigal versus enzyme replacement therapy (ERT) in Fabry patients. Amicus and its partner Shire Human Genetic Therapies, Inc. (Shire HGT) plan additional discussions with the EMEA to finalize the design of this study.

In parallel with the Phase 3 regulatory discussions, 23 of the original 26 patients from the Phase 2 studies continue to be treated in a voluntary extension study to characterize the long-term safety and efficacy of Amigal and to evaluate additional doses and dose regimens. Amicus expects data from this extension study to be available in the first quarter of 2009.

Plicera(TM) (isofagomine tartrate) for the treatment of Gaucher Disease

During the fourth quarter, Amicus also focused on executing its ongoing Phase 2 clinical trial of Plicera in Gaucher disease. This 6-month study is designed to evaluate safety and to demonstrate trends of efficacy, as measured by the standard endpoints in Gaucher disease. Amicus previously reported that target enrollment is expected to be surpassed in the study and the Company expects the results to be available in the third quarter of 2009.

Amicus will continue to work closely with its partner, Shire HGT, to prepare for Phase 3 development of Plicera p
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
2. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
3. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
4. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
5. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
6. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
7. Amicus Therapeutics Opens Research Facility in San Diego
8. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
9. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
10. Amicus Therapeutics Announces First Quarter 2008 Financial Results
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... TORONTO , Sept. 22, 2014 ... (OTCBB:GNBT) today announced that it has entered into ... to which UHN,s Centre for Molecular Design and ... refinement project.  The goal of the project is ... the Company,s proprietary buccal insulin spray product, thereby ...
(Date:9/22/2014)... 22, 2014 FierceBiotech today announced its ... biotechnology companies of 2014. FierceBiotech editors John Carroll ... this year’s winners. Those selected are identified as ... the industry. , "It's always a lot ... Fierce 15 companies," said Carroll. "This year in particular ...
(Date:9/22/2014)... The US markets on Friday, ... the Dow Jones Industrial Average finished at 17,279.74, up ... 0.30%. The S&P 500 finished the session 0.05% lower ... ten sectors finished on a positive note. The S&P ... 751.48, up 0.10%, with the index gaining 6.95% in ...
(Date:9/22/2014)... , Sept. 22, 2014 ... GEVA ), a biopharmaceutical company developing therapeutic products ... Robert Bazemore as Chief Operating Officer.  ... President and Chief Executive Officer, Robert will oversee ... lead program, sebelipase alfa for LAL Deficiency, and ...
Breaking Biology Technology:Generex Collaborates with University Health Network for Buccal Insulin Project 2Generex Collaborates with University Health Network for Buccal Insulin Project 3Generex Collaborates with University Health Network for Buccal Insulin Project 4FierceBiotech Announces Annual “Fierce 15” Winners of 2014 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 3Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 4
... Students, faculty and supporters of The University of Texas ... state-of-the-art Engineering Research Building with a March 4 dedication ... ) The landmark center is UT ... by College of Engineering and College ...
... PITTSBURGH, March 1, 2011 D3 Oncology Solutions ... Via Oncology Pathways for medical oncology to the ... D3 now offers integrated pathways programs to both ... Via Oncology Pathways are evidence-based clinical algorithms that ...
... 2011 Iverson Genetic Diagnostics, Inc. announced today that the ... R eduction f or A dults R ... at WellStar Health System in Marietta and other major hospital ... determine a personalized warfarin dose for individual patients to reduce ...
Cached Biology Technology:UT Arlington Honors Collaborative Research During March 4 Engineering Research Building Dedication 2UT Arlington Honors Collaborative Research During March 4 Engineering Research Building Dedication 3D3 Oncology Solutions Now Includes Via Oncology Pathways for Medical Oncology 2WARFARIN Study Launched at WellStar Health System to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 2WARFARIN Study Launched at WellStar Health System to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 3WARFARIN Study Launched at WellStar Health System to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 4
(Date:9/22/2014)... 22, 2014Cassava, also known as tapioca, has large starch-filled ... of Africa, Asia, and Latin America where corn and ... novel enzymes and processes designed to break down tapioca ... produce sweeteners such as glucose, fructose, or maltose syrup, ... described in a Review article in Industrial Biotechnology ...
(Date:9/22/2014)... institutions in the country selected by the National ... BEST Award a $2 million grant designed ... biomedical sciences graduate trainees to career opportunities that ... traditionally taken. , The award funds development of ... (iJOBs) program. It includes courses, seminars, shadowing, mentoring ...
(Date:9/22/2014)... in the wake of the huge King Fire blazing ... The King Fire is burning in steep terrain in ... Creek Canyon, and the Rubicon Canyon, north of the ... Placer County and burned onto the Tahoe National Forest ... is expected to be minimal on Sept. 22 due ...
Breaking Biology News(10 mins):Rutgers receives $2 million grant to prepare biomedical students for roles in industry 2Rutgers receives $2 million grant to prepare biomedical students for roles in industry 3
... good chance that forest fires in the Pacific Northwest will ... expert speaking today at a professional conference, that,s just fine. ... to predict, will always be variable, and undoubtedly a part ... is not only inevitable but also a valuable part of ...
... feet were built the same way as a mongoose,s feet, they,d ... support the big cat,s weight. But they,re not. For decades, ... put together across the four-legged animal kingdom, but until now they ... foot that bear the brunt of the animal,s walking and running. ...
... particles called neutrons are poised to play a big ... manufacturing processes. The reason: They are the focus of ... to study the chemistry of a wide range of ... a fascinating article in Chemical & Engineering News ...
Cached Biology News:More frequent fires could aid ecosystems 2More frequent fires could aid ecosystems 3The bigger the animal, the stiffer the 'shoes' 2
... Blot Processing mini Tray (3 per ... gel staining and blot processing.Automated staining ... for proteins and nucleic acid analysis.Prepares ... and chromogenic detection.Programmable control of protocol, ...
L1 Protein of Human Papilloma Virus Purified Anti-Viral-transformed cells clone CAMVIR-1, Isotype Mouse IgG 2a , 0.1 mg Consult technical datasheet for details....
... 1 g. High quality kits ... preparation that give consistent and ... and tissues.Clean up samples from ... Accurately quantitate protein for first-dimension ...
... Varian Cary 50 Microplate Reader ... cost per analysis by extending ... the award-winning Cary 50 instruments. ... to 384 samples in microlitre ...
Biology Products: